What Evelo Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Gill Simba | President & CEO | Nov 08 | Open-market sale · S | −172 | $0.33 | −$56.8 | 17,758 |
| Bodmer Mark | CSO, President of R&D | Nov 08 | Open-market sale · S | −3,163 | $0.33 | −$1.04K | 25,732 |
| Thorell Marella | Chief Financial Officer | Nov 08 | Open-market sale · S | −1,811 | $0.33 | −$598 | 22,259 |
| McHale Duncan | Chief Medical Officer | Nov 08 | Open-market sale · S | −3,103 | $0.33 | −$1.02K | 16,984 |
| Gill Simba | President & CEO | Nov 07 | Exercise / conversion · M | +1,172 | — | — | 17,930 |
| Bodmer Mark | CSO, President of R&D | Nov 07 | Exercise / conversion · M | +6,625 | — | — | 28,895 |
| Thorell Marella | Chief Financial Officer | Nov 07 | Exercise / conversion · M | +6,500 | — | — | 24,070 |
| McHale Duncan | Chief Medical Officer | Nov 07 | Exercise / conversion · M | +6,500 | — | — | 20,087 |
| Thorell Marella | Chief Financial Officer | Nov 02 | Open-market sale · S | −3,999 | $0.33 | −$1.32K | 17,570 |
| McHale Duncan | Chief Medical Officer | Nov 02 | Open-market sale · S | −6,854 | $0.33 | −$2.26K | 13,587 |
| Bodmer Mark | CSO, President of R&D | Nov 02 | Open-market sale · S | −6,854 | $0.33 | −$2.26K | 22,270 |
| Thorell Marella | Chief Financial Officer | Nov 01 | Exercise / conversion · M | +12,500 | — | — | 21,569 |
| McHale Duncan | Chief Medical Officer | Nov 01 | Exercise / conversion · M | +12,500 | — | — | 20,441 |
| Bodmer Mark | CSO, President of R&D | Nov 01 | Exercise / conversion · M | +12,500 | — | — | 29,124 |
| Gill Simba | President & CEO | Sep 28 | Open-market sale · S | −1,996 | $3.94 | −$7.86K | 16,758 |
| Gill Simba | President & CEO | Sep 27 | Exercise / conversion · M | +15,000 | — | — | 18,754 |
| Gill Simba | President & CEO | Aug 08 | Open-market sale · S | −342 | $9.51 | −$3.25K | 3,754 |
| Thorell Marella | Chief Financial Officer | Aug 08 | Open-market sale · S | −2,004 | $9.51 | −$19.1K | 9,069 |
| McHale Duncan | Chief Medical Officer | Aug 08 | Open-market sale · S | −3,434 | $9.51 | −$32.7K | 7,941 |
| Bodmer Mark | CSO, President of R&D | Aug 08 | Open-market sale · S | −3,128 | $9.51 | −$29.7K | 16,624 |
Loading...
